Please see the following relevant documents:
- Affordable and sustainable patient access to personalised medicine
Personalized medicine, or PM, promises to revolutionize healthcare, with its key goal of providing the right treatment to the right patient at the right time. It holds the potential to substantially improve patient care and patient outcomes while supporting efforts aiming at more efficient healthcare systems. PM has the potential to optimize the delivery and dosing of treatments so patients can receive the most benefit at the least amount of risk and harm, eliminating both the unnecessary side effects of toxic treatments such as chemotherapy and the delays associated with the “trial-and-error” process that many patients endure to obtain the correct diagnosis and treatment for their condition.
Download (106.50 KB)
- An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe
Personalised medicine (PM) is an innovative way to produce better patient outcomes by using an individualised or stratified approach to disease and treatment rather than a collective treatment approach for patients. Despite its tangible advantages, the complex process to translate PM into the member states and European healthcare systems has delayed its uptake. The aim of this study is to identify relevant barriers represented by an index to summarise challenging areas for the implementation of PM in Europe.
Download (191.80 KB)
Please see the following relevant PowerPoint presentation: